DISCLOSED: 5 Stocks Congress Just Bought (Washington's New Whale)

Members of Congress are still actively trading the stock market — and their latest moves are drawing attention from retail investors. Get the FREE Report on 5 Stocks To Cushion Your Portfolio Through Volatility: https://www.marketbeat.com/y/5highyield In this video, MarketBeat analyst Chris Markoch breaks down five recent congressional stock trades and what they could signal for the AI trade, small-cap stocks, consumer staples, semiconductor stocks, and the booming GLP-1 weight-loss drug market. Some lawmakers are making short-term trades, while others appear to be building positions in companies tied to defense contracts, AI infrastructure, and major healthcare breakthroughs. But should investors actually follow congressional trading activity? Watch as we analyze the timing, fundamentals, and analyst outlook behind these latest trades — and discuss whether congressional buys are useful as a stock research signal or just another data point for investors. Video Chapters: 00:00 Introduction 01:12 Stock 1 05:16 Stock 2 08:24 Stock 3 13:45 Stock 4 17:01 Stock 5 View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.